Bookmark and Share
BioAssay: AID 504634

Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)

Name: Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A). ..more
_
   
 Tested Compounds
 Tested Compounds
All(335227)
 
 
Active(279)
 
 
Inactive(334948)
 
 
 Tested Substances
 Tested Substances
All(335461)
 
 
Active(279)
 
 
Inactive(335182)
 
 
AID: 504634
Data Source: The Scripps Research Institute Molecular Screening Center (HTR5A_IAG_LUMI_1536_1X%INH)
BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
Deposit Date: 2011-04-03
Modify Date: 2011-04-07

Data Table ( Complete ):           Active    All
Target
BioActive Compounds: 279
Depositor Specified Assays
Show more
AIDNameTypeComment
504357Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptorsscreeningPrimary screen (inverse agonists of OPRM1 and OPRD1 in singlicate)
504368Summary of the probe development efforts to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptorssummarySummary (inverse agonists of OPRM1 and OPRD1)
504355Summary of the probe development efforts to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptorssummary
651765Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response HTR5A counterscreen, Set 2confirmatory
651764Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response OPRD1 counterscreen, Set 2confirmatory
504914Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)screening
504916Luminescence-based cell-based high throughput confirmation assay for inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)screening
651686Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response OPRD1 counterscreenconfirmatory
651689Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response OPRM1 counterscreenconfirmatory
504900Luminescence-based cell-based high throughput confirmation assay for inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptorsscreening
651762Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response assay, Set 2confirmatory
504912Counterscreen for inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A): Luminescence-based cell-based high throughput assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptorsscreening
651685Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response assayconfirmatory
651688Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response HTR5A counterscreenconfirmatory
651769Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response OPRM1 counterscreen, Set 2confirmatory
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)
Affiliation: The Scripps Research Institute, TSRI
Assay Provider: Lakshmi A. Devi, Mount Sinai School of Medicine
Network: Molecular Library Probe Production Centers Network (MLPCN)
Grant Proposal Number: R03NS053751
Grant Proposal PI: Lakshmi A. Devi, Mount Sinai School of Medicine
External Assay ID: HTR5A_IAG_LUMI_1536_1X%INH

Name: Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A).

Description:

Opiates such as morphine are the choice analgesic in the treatment of chronic pain due to their potent and rapid action. However, their long-term use is limited because of the development of tolerance and dependence, as well as respiratory suppression and constipation (1). Due to their clinical importance, various strategies have been considered for making opiates more effective while curbing liabilities such as addiction. One such strategy has been to use a combination of drugs to improve the effectiveness of morphine. The OPRM1 gene encodes the mu opioid receptor, which is the primary site of action for morphine (2) and other commonly used opioid such as heroin, fentanyl, and methadone. OPRM1 activation and subsequent dissociation of the Gi/Go G-proteins results in reduction of adenylyl cyclase-mediated cAMP production (3). There are at least two other types of opioid receptors: delta (OPRD1) and kappa (OPRK1), each with a distinct pharmacologic profile. In particular, delta (OPRD1) opioid receptor ligands have been useful in enhancing morphines potency, but the underlying molecular basis is not understood (4). It has been shown that modulation of receptor function by physical association between mu and delta opioid receptors is a potential mechanism (5). The assay provider has previously found that a combination of OPRM1 agonist with OPRD1 antagonist selectively activates the OPRM1-OPRD1 heteromer (5) and recently showed that this could be blocked by antibodies that selectively recognize the heteromer (6). Since OPRD1 antagonist have anxiogenic effects, these are not ideal as therapies. Hence, the identification of compounds that selectively activate mudelta opioid receptor heterodimerization may have potential in the treatment of pain and alleviate unwanted effects associated with opiate use.

References:

1. Raehal KM, Bohn LM. Mu opioid receptor regulation and opiate responsiveness. AAPS J. 2005 Oct 19;7(3):E587-91.
2. Matthes H, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P, Tzavara E, Hanoune J, Roques B, Kieffer B (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383:819-823.
3. Maguea SD and Blendy JAOPRM1 SNP (A118G): Involvement in disease development, treatment response, and animal models. Drug and Alcohol Dependence. 2010 May 108 (3): 172-182.
4. Traynor J, Elliot J. Delta-opioid receptor subtypes and cross talk with mu-receptors. Trends Pharmacol Sci 1993 14:84-86.
5. Gomes I, Jordan BA, Gupta A, Trapaidze N, Nagy V, Devi LA. Heterodimerization of mu and delta opioid receptors: A role in opiate synergy. J Neurosci. 2000 Nov 15;20(22):RC110.
6. Gupta, A., Mulder, J., Gomes, I., Rozenfeld, R., Bushlin, I., Ong, E., Lim, M., Maillet, E., Junek, M., Cahill, C.M., Harkany, T. Devi, L.A. Increased abundance of opioid receptor heteromers after chronic morphine administration. Science Signaling 3:ra54, 2010

Keywords:

OPRM1, MOR-1, mu, delta, OPRD1, opioid, receptor, GPCR, beta-arrestin, counterscreen, full deck, singlicate, artifact, HTR5A, HTR5A, HTR5A, MGC138226, serotonin receptor 5A, U2OS, PathHunter, complementation, reconstitution, enzyme, beta-gal, beta-galactosidase, lumi, luminescence, luminescent, chemiluminescence, GPCR, receptor, inverse agonist, inhibit, inhibitor, dimer, heterodimer, homodimer, pain, HTS, high throughput screen, 1536, Scripps Florida, The Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN.
Protocol
Assay Overview:

The purpose of this assay is to identify compounds that inhibit the HTR5A (5HT5A) serotonin receptor, thereby preventing or reducing the membrane recruitment of beta-arrestin. This assay also serves as a counterscreen to determine whether compounds are non-selective GPCR inhibitors/inverse agonists. The assay monitors GPCR-beta-arrestin proximity using low affinity fragment complementation of beta-galactosidase (beta-gal). This assay employs U2OS cells which express HTR5A fused to a beta-gal peptide fragment (enzyme donor), and beta-arrestin fused to the complementary beta-gal fragment (enzyme acceptor). Cells are incubated with test compound, followed by measurement of well luminescence. As designed, compounds that inhibit HTR5A will prevent beta-arrestin recruitment, thereby reducing the reconstitution of the beta-gal holoenzyme. The decrease in reconstituted holoenzyme will reduce the hydrolysis of a substrate which yields a chemiluminescent signal, resulting in decreased well luminescence. Wells containing Cell Plating Media (No cells) and treated with DMSO will be used as the high (100% RLU) control for inverse agonists, and wells containing cells treated with DMSO will be used as the low (0% RLU) control. Compounds were tested in singlicate at a final nominal concentration of 9.3 uM.

Protocol Summary:

The U2OS-HTR5A cell line was routinely cultured in T-175 sq cm flasks at 37 C and 95% relative humidity (RH). The growth media consisted of a 1:1 mixture of Hams F-12 Nutrient Media (F-12) and Dulbeccos Modified Eagle Media (DMEM) supplemented with 10% v/v heat-inactivated certified fetal bovine serum, 25 mM HEPES, 250 ug/mL Geneticin, 250 ug/mL Hygromycin B, and 1X antibiotic mix (penicillin, streptomycin, and neomycin).

The day before the assay 1000 cells in 3 uL of cell plating media were seeded into each well of 1536 well microtiter plates and allowed to incubate at 37 C, 5% CO2, and 95 % RH for 23 hours. Next, 28 nL of test compound in DMSO, or DMSO alone were dispensed to the appropriate wells. The plates were then incubated for 3 hours at 37 C, 5% CO2, and 95 % RH. The assay was started by adding 2 uL of PathHunter reagent (prepared according to the manufacturer's protocol); followed by 1 hour incubation at room temperature. Then, Well Luminescence was read on the ViewLux plate reader

The percent inhibition for each compound was calculated as follows:

%_Inhibition = ( ( RLU_Test_Compound - Median_RLU_Low_Control ) / ( Median_RLU_High_Control - Median_RLU_Low_Control ) ) * 100

Where:

High_Control is defined as wells containing no cells and DMSO,
Test_Compound is defined as wells containing cells, test compounds and DMSO,
Low_Control is defined as wells containing cells and DMSO.

A mathematical algorithm was used to determine nominally inhibiting compounds in the primary screen. Four values were calculated for each assay plate:

(1) The average percent inhibition of Low control wells;
(2) Three times the standard deviation of this subset;
(3) The average percent inhibition of test compound wells with percent inhibition greater than the difference of (1) and (2);
(4) Three times the standard deviation of this subset.

The sum of (3) and (4) was used as a cutoff parameter for each plate, i.e. any compound that exhibited greater % inhibition than that particular plate's cutoff parameter was declared active.

A mathematical algorithm was used to determine nominally inhibiting compounds in the screen. Two values were calculated: (1) the average percent inhibition of all compounds tested, and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter, i.e. any compound that exhibited greater % inhibition than the cutoff parameter was declared active.

PubChem Activity Outcome and Score:

The reported PubChem Activity Score has been normalized to 100% observed primary inhibition. Negative % inhibition values are reported as activity score zero.

In this assay not all plates were run in the same batch. This resulted in batch-to-batch variation among the different batches of plates, thereby necessitating the use of a plate-based activity cutoff. For this reason the inactive and active scores overlap.

The PubChem Activity Score range for active compounds is 100-17, and for inactive compounds 58-0.

List of Reagents:

PathHunter B-arrestin recruitment assay, containing the U2OS HTR5A Beta-arrestin cell line; PathHunter Detection Kit (DiscoveRx, part, 93-0700C3)
Ham's F-12 media (Invitrogen, part 11765-054)
DMEM media (Invitrogen, part 11995-073)
Detachin (Genlantis, part T100100)
Heat Inactivated Fetal Bovine Serum (Invitrogen, part 10082-147)
Hygromycin B (Invitrogen, part 10687-010)
Geneticin (Invitrogen, part 10131-027)
100X Penicillin-Streptomycin-Neomycin mix (Invitrogen, part 15640-055)
T-175 tissue culture flasks (Nunc, part 159910)
Agonist: Serotonin hydrochloride (5HT) (Sigma-Aldrich, part H9523)
1536-well plates (Greiner, part 789173)
Comment
Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1Inhibition at 9.3 uM (9.3μM**)Normalized percent inhibition of the screen at a compound concentration of 9.3 micromolar.Float%

** Test Concentration.
Additional Information
Grant Number: R03NS053751

Data Table (Concise)
Classification
PageFrom: